Skip to main content

MGTX

Stock
Health Care
Biotechnology

Performance overview

MGTX Price
Price Chart

Forward-looking statistics

Beta
1.38
Risk
60.94%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Company info

SectorHealth Care
IndustryBiotechnology
Employees383
Market cap$306.7M

Fundamentals

Enterprise value$538.3M
Revenue$34.5M
Revenue per employee—
Profit margin28.51%
Debt to equity244.35

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.31
Dividend per share—
Revenue per share$0.47
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$4M
Put-call ratio—

Macro factor sensitivity

Growth-2.4
Credit+10.3
Liquidity+1.3
Inflation-5.0
Commodities-2.1
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio9.05
Price to sales17.49
P/E Ratio9.05
Enterprise Value to Revenue15.60
Price to book18.01

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Zacks Investment Research (June 27, 2025)
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

On Thursday, MeiraGTx Holdings plc MGTX announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development.

Benzinga (March 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free